Inclusion Criteria:~* Clinical diagnosis of Mild to Moderate Alzheimer's disease (MMSE 16-26)~* 6 Month
cognitive decline~* Stable marketed AD therapy x2 months or additional marketed AD therapy during study~* Score
of â‰¤4 on the Modified Hachinski Ischemia Scale~* CT results consistent with Alzheimer's disease~* Medically
stable~* 6 years education~* Reliable study partner (caregiver)~* Must be able to swallow capsules~
